Press & Media Coverage
Catch up on our latest press coverage
October 2023 Newsletter
Our October Newsletter Highlights: 🔹 Scientific poster accepted at AACR Ovarian Cancer Conference 🔹 Strategic partnership signed with Prestige Biopharma for pancreatic cancer 🔹 Imagion
Investor Update: Operating Expenses and MagSense HER2 Program
Highlights: Reduces operating expenses Update on MagSense® HER2 program MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Half-Year Results
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion
Shareholder Letter from CEO July 2023
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.